Cardona, DM, Detweiler, CJ, Shealy, MJ, Sung, AD, Wild, DM, Poleski, MH, Balmadrid, BL, Cirrincione, CT, Howell, DN, and Sullivan, KM. "Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease." Archives of Pathology & Laboratory Medicine 142, no. 9 (September 2018): 1098-1105.
Sung, AD, Hassan, S, Cardona, DM, Wild, D, Nichols, KR, Mehdikhani, H, Balmadrid, B, Detweiler, CJ, Shealy, M, Cirrincione, C, Li, Z, Poleski, M, Dalton, TE, Siamakpour-Reihani, S, Chao, NJ, and Sullivan, KM. "Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 24, no. 4 (April 2018): 734-740.
Wild, D, Sung, AD, Cardona, D, Cirricione, C, Sullivan, K, Detweiler, C, Shealy, M, Balmadrid, B, Rowes, KL, Chao, N, Piryani, S, Karimabad, HM, Martin, P, and Poleski, M. "The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review." Digestive Diseases and Sciences 61, no. 3 (March 2016): 806-813.
Coutré, SE, Barrientos, JC, Brown, JR, de Vos, S, Furman, RR, Keating, MJ, Li, D, O'Brien, SM, Pagel, JM, Poleski, MH, Sharman, JP, Yao, N-S, and Zelenetz, AD. "Management of adverse events associated with idelalisib treatment: expert panel opinion." Leukemia & Lymphoma 56, no. 10 (January 2015): 2779-2786. (Review)
Shah, TU, Liddle, R, Branch, MS, Jowell, P, Obando, J, and Poleski, M. "Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial." Jop : Journal of the Pancreas 13, no. 5 (September 10, 2012): 514-518.
Faes, SK, Untch, BR, Edwards, C, Turner, J, Poleski, M, and Tyler, DS. "Management of Dieulafoy’s Lesions." (2010): 31-37.
Willett, CG, Duda, DG, Ancukiewicz, M, Shah, M, Czito, BG, Bentley, R, Poleski, M, Fujita, H, Lauwers, GY, Carroll, M, Tyler, D, Mantyh, C, Shellito, P, Chung, DC, Clark, JW, and Jain, RK. "A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer." Oncologist 15, no. 8 (2010): 845-851.
Duda, DG, Willett, CG, Ancukiewicz, M, di Tomaso, E, Shah, M, Czito, BG, Bentley, R, Poleski, M, Lauwers, GY, Carroll, M, Tyler, D, Mantyh, C, Shellito, P, Clark, JW, and Jain, RK. "Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer." Oncologist 15, no. 6 (2010): 577-583.
Xu, L, Duda, DG, di Tomaso, E, Ancukiewicz, M, Chung, DC, Lauwers, GY, Samuel, R, Shellito, P, Czito, BG, Lin, P-C, Poleski, M, Bentley, R, Clark, JW, Willett, CG, and Jain, RK. "Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer." Cancer Res 69, no. 20 (October 15, 2009): 7905-7910.
Willett, CG, Duda, DG, di Tomaso, E, Boucher, Y, Ancukiewicz, M, Sahani, DV, Lahdenranta, J, Chung, DC, Fischman, AJ, Lauwers, GY, Shellito, P, Czito, BG, Wong, TZ, Paulson, E, Poleski, M, Vujaskovic, Z, Bentley, R, Chen, HX, Clark, JW, and Jain, RK. "Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study." J Clin Oncol 27, no. 18 (June 20, 2009): 3020-3026.